Alyeska Investment Group
VRTX icon

Alyeska Investment Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Alyeska Investment Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-354,334
Closed -$161M – 755
2025
Q4 		$161M Buy
354,334
+87,165
+33% +$37.6M 0.45% 44
2025
Q3 		$105M Buy
267,169
+202,169
+311% +$84.5M 0.32% 84
2025
Q2 		$28.9M Sell
65,000
-366,804
-85% -$169M 0.1% 230
2025
Q1 		$209M Buy
431,804
+354,269
+457% +$165M 0.83% 19
2024
Q4 		$31.2M Buy
77,535
+74,182
+2,212% +$34.4M 0.12% 208
2024
Q3 		$1.56M Buy
+3,353
New +$1.61M 0.01% 436
2023
Q3 		– Sell
-162,049
Closed -$57M – 638
2023
Q2 		$57M Buy
+162,049
New +$54.6M 0.42% 75
2021
Q2 		– Sell
-95,881
Closed -$20.6M – 852
2021
Q1 		$20.6M Buy
+95,881
New +$21.1M 0.27% 111
2019
Q3 		– Sell
-3,811
Closed -$699K – 504
2019
Q2 		$699K Buy
+3,811
New +$666K 0.01% 389
2017
Q3 		– Sell
-7,503
Closed -$967K – 539
2017
Q2 		$967K Sell
7,503
-112,686
-94% -$13.6M 0.01% 414
2017
Q1 		$13.1M Sell
120,189
-101,845
-46% -$8.97M 0.11% 235
2016
Q4 		$16.4M Buy
222,034
+97,034
+78% +$7.9M 0.14% 231
2016
Q3 		$10.9M Buy
+125,000
New +$11.8M 0.1% 252
2016
Q1 		– Sell
-269,490
Closed -$33.9M – 455
2015
Q4 		$33.9M Sell
269,490
-133,865
-33% -$16.2M 0.36% 113
2015
Q3 		$42M Buy
403,355
+252,575
+168% +$32.4M 0.49% 71
2015
Q2 		$18.6M Sell
150,780
-8,708
-5% -$1.1M 0.21% 160
2015
Q1 		$18.8M Buy
159,488
+8,020
+5% +$961K 0.26% 155
2014
Q4 		$18M Buy
151,468
+107,718
+246% +$12.1M 0.31% 117
2014
Q3 		$4.91M Buy
+43,750
New +$4.17M 0.1% 225
2013
Q3 		– Sell
-85,000
Closed -$6.8M – 353
2013
Q2 		$6.8M Buy
+85,000
New +$6.26M 0.33% 96

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Alyeska Investment Group's VRTX Position: Q1 2026 in Review

Alyeska Investment Group sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 354,334 shares — an estimated $161M sold.

Alyeska Investment Group first reported a position in VRTX in Q2 2013 and held it in 20 quarters. The position peaked at $209M in Q1 2025. 1,695 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Alyeska Investment Group reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Alyeska Investment Group sold 354,334 Vertex Pharmaceuticals shares in Q1 2026, an estimated $161M.
  • Alyeska Investment Group first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 20 quarters.
  • Alyeska Investment Group's Vertex Pharmaceuticals position peaked at $209M in Q1 2025.
  • 1,695 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Alyeska Investment Group's 13F filing for Q1 2026, filed 15 May 2026.